These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32157264)

  • 1. [Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.].
    Palazzo G
    Recenti Prog Med; 2020 Mar; 111(3):160-166. PubMed ID: 32157264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
    Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
    Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
    Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
    Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Successful treatment of relapse/refractory multiple myeloma with carfilzomib, lenalidomide, and dexamethasone combination therapy following allogeneic bone marrow transplantation].
    Fuchida SI; Shimura K; Taminishi-Katsuragawa Y; Matsui-Maegawa S; Okano A; Hatsuse M; Murakami S; Shimazaki C
    Rinsho Ketsueki; 2019; 60(10):1468-1470. PubMed ID: 31695009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
    Jasielec JK; Kubicki T; Raje N; Vij R; Reece D; Berdeja J; Derman BA; Rosenbaum CA; Richardson P; Gurbuxani S; Major S; Wolfe B; Stefka AT; Stephens L; Tinari KM; Hycner T; Rojek AE; Dytfeld D; Griffith KA; Zimmerman TM; Jakubowiak AJ
    Blood; 2020 Nov; 136(22):2513-2523. PubMed ID: 32735641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report.
    Vo K; Guan T; Banerjee R; Lo M; Young R; Shah N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1244-1248. PubMed ID: 35084252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
    Stewart AK; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Buchanan J; Cocks K; Yang X; Xing B; Zojwalla N; Tonda M; Moreau P; Palumbo A
    J Clin Oncol; 2016 Nov; 34(32):3921-3930. PubMed ID: 27601539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
    Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A
    Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
    Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
    Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
    Ueda S; Kubo M; Matsuura N; Matsunaga H; Kataoka S; Maeda T; Inui Y; Kawata S; Kanakura Y
    Intern Med; 2013; 52(11):1235-8. PubMed ID: 23728562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
    Rocchi S; Tacchetti P; Pantani L; Mancuso K; Rizzello I; di Giovanni Bezzi C; Scalese M; Dozza L; Marzocchi G; Martello M; Barilà G; Antonioli E; Staderini M; Buda G; Petrini M; Cea M; Quaresima M; Furlan A; Bonalumi A; Cavo M; Zamagni E
    Hematol Oncol; 2021 Feb; 39(1):41-50. PubMed ID: 33085797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients.
    Palmieri S; Rocco S; Vitagliano O; Catalano L; Cerchione C; Vincelli ID; Scopelliti A; Gentile M; Farina G; Barone M; Gagliardi A; Esposito D; Arcamone M; Amico V; Fontana R; Sementa A; Sica A; Svanera G; Pane F; Ferrara F
    Ann Hematol; 2020 Dec; 99(12):2903-2909. PubMed ID: 32583088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early relapse after complete remission of primary plasma cell leukaemia manifesting clonal evolution: A case report.
    Nyunt WWT; Abdul Jalil D; Zakariah NA; Abdul Karim N; Mohd Idris MR; Nasuruddin DN; Salwati SHUIB; Alauddin H; Tumian NR; Leong CF; Abdul Wahid SFS
    Malays J Pathol; 2020 Apr; 42(1):143-150. PubMed ID: 32342945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.
    Bhutani M; Foureau DM; Robinson M; Guo F; Fesenkova K; Atrash S; Paul B; Varga C; Friend R; Pineda-Roman M; Rigby K; Symanowski JT; Norek S; Tucker MR; Druhan LJ; Voorhees PM; Usmani SZ
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):535-544.e1. PubMed ID: 37127471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
    Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
    J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
    Alsina M; Landgren O; Raje N; Niesvizky R; Bensinger WI; Berdeja JG; Kovacsovics T; Vesole DH; Fang B; Kimball AS; Siegel DS
    Am J Hematol; 2021 Feb; 96(2):226-233. PubMed ID: 33125764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
    Avet-Loiseau H; Fonseca R; Siegel D; Dimopoulos MA; Špička I; Masszi T; Hájek R; Rosiñol L; Goranova-Marinova V; Mihaylov G; Maisnar V; Mateos MV; Wang M; Niesvizky R; Oriol A; Jakubowiak A; Minarik J; Palumbo A; Bensinger W; Kukreti V; Ben-Yehuda D; Stewart AK; Obreja M; Moreau P
    Blood; 2016 Sep; 128(9):1174-80. PubMed ID: 27439911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
    Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
    Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
    Kazandjian D; Hill E; Dew A; Morrison C; Roswarski J; Korde N; Emanuel M; Petrosyan A; Bhutani M; Calvo KR; Dulau-Florea A; Kwok M; Lee MJ; Lee S; Lindenberg L; Mailankody S; Manasanch E; Maric I; Mena E; Patel N; Tageja N; Trepel JB; Turkbey B; Wang HW; Wang W; Yuan C; Zhang Y; Braylan R; Choyke P; Stetler-Stevenson M; Steinberg SM; Figg WD; Roschewski M; Landgren O
    JAMA Oncol; 2021 Nov; 7(11):1678-1685. PubMed ID: 34529025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.